Samantha DU
Founder, CEO, & Chair @ Zai Lab
Shanghai, China
Samantha DU is a startup investor at Zai Lab in Shanghai. Samantha Du is Founder, Chairperson and Chief Executive Officer. During her career, she has been a successful drug developer, entrepreneur, and investor. Dr. Du joined Pfizer in the US in 1994, where she was involved in the development of multiple early and late-stage products, two of which received US FDA approval. She also led the scientific sideof Pfizer’s global metabolic licensing group. Dr. Du co-founded Hutchison MediPharma (HMP) and Hutchison China MediTech (Chi-Med, now HUTCHMED) where she served as Chief Executive Officer and Chief Scientific Officer, respectively. She then joined Sequoia Capital China in 2012 as a Managing Director responsible for several healthcare investments. Dr. Du founded Zai Lab in 2014 to address the unmet medical needs for patients globally.
Last updated:
For AI agents: llms.txt
About Zai Lab
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broadpipeline of innovative drug candidates.They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China.Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.
Zai Lab Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Billy Cho
Chief Financial Officer
|
|||
Harald Reinhart
Chief Medical Officer, Autoimmune and Infectious Diseases
|
|||
|
Samantha DU
Founder, CEO, & Chair
|
|||
William Liang
Chief Commercial Officer & President of Greater China
|
|||
Yongjiang Hei
Chief Medical Officer, Oncology
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
